What is Positron?
Positron Corporation is a key player in the nuclear medicine sector, focusing on advanced cardiac PET imaging systems and related services within the United States. The company provides comprehensive solutions, including PET molecular imaging systems, clinical support, automated radiopharmaceutical systems, and radiopharmaceutical processing. Positron's Attrius system is designed to enhance the accuracy of heart disease diagnosis, improve patient outcomes, and promote cost-effective medical practices. Furthermore, the company is actively involved in increasing the supply of Sr-82, a critical radioisotope, through processing and recycling efforts. Founded in 1983 and based in Westmont, Positron has established a long-standing presence in the healthcare technology landscape.
How much funding has Positron raised?
Positron has raised a total of $33.6M across 4 funding rounds:
Debt
$66K
Multiple Rounds
$33.5M
Debt (2021): $66K with participation from PPP
Angel/Seed (2025): $23.5M led by Valor Equity Partners, Flume Ventures, and Atreides Management
Share Placement (2025): $8M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Key Investors in Positron
Valor Equity Partners
Valor Equity Partners, established in 2001 and based in Chicago, Illinois, is a financial services firm specializing in investment activities, likely focusing on companies with significant growth potential.
Flume Ventures
Flume Ventures is a venture capital firm comprised of experienced operators and founders, dedicated to partnering with visionary entrepreneurs to scale innovative ideas, providing mentorship and strategic support.
Atreides Management
Atreides Management, founded in 2019 and headquartered in Boston, Massachusetts, is an investment firm with a long-term perspective, focusing on technology and consumer businesses in both public and private markets.
What's next for Positron?
With the recent major strategic investment, Positron is poised for significant growth and innovation. This capital infusion is expected to accelerate the development and deployment of its cardiac PET imaging technologies, potentially expanding its market reach and enhancing its product offerings. The company's focus on improving diagnostic accuracy and patient outcomes aligns with the increasing demand for advanced medical imaging solutions. Future strategic initiatives will likely involve further research and development, potential partnerships, and scaling operational capabilities to meet market demands, solidifying its position as a leader in nuclear medicine.
See full Positron company page
